Veritas In Silico

Basic Information

Stock Code
130A
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
November 2016
Listing Year
February 2024
Official Website
https://www.veritasinsilico.com/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Cocolive, JSH, Wolves Hand, GNI Group, Heartseed, Nexela Pharma, PeptiDream, SanBio, Helios, Rena Science, QualiPs, Takara Bio, Japan Tissue Engineering

Overview

Veritas In Silico is a drug discovery venture founded in 2016 in the pharmaceutical industry, featuring advanced new drug development targeting messenger RNA and collaborations with pharmaceutical companies.

Current Situation

Veritas In Silico expanded its business foundation centered on drug discovery development in fiscal 2023, strengthening its competitiveness in pharmaceutical R&D through partnerships with multiple pharmaceutical companies. Focusing on therapeutics targeting messenger RNA, it promotes technological innovation in the bio-pharmaceutical field. After successful fundraising, it listed on the Tokyo Stock Exchange Growth Market in February 2024, bolstering its financial resources. It is enhancing its R&D structure and advancing collaborations with external companies to accelerate next-generation pharmaceutical development. In terms of sustainability, it aims for low-environmental-impact technology development and contributions to sustainable healthcare. In the medium to long term, it aspires to transform into a specialized pharmaceutical manufacturer and enhance its presence in the global market by 2030. It is actively pursuing the latest technology developments and investments, including drug discovery efficiency via AI utilization and novel target exploration.

Trivia

Interesting Facts

  • One of Japan's leading venture companies specialized in messenger RNA target drug discovery.
  • Achieved TSE Growth Market listing in just 8 years since founding.
  • Has strategic partnerships with numerous domestic and international pharmaceutical companies.
  • Significantly streamlines drug discovery processes by integrating proprietary AI technology.
  • Deploys comprehensive drug discovery support services.
  • One of few companies handling manufacturing and sales of gene-related reagents.
  • Invests over 20% of sales in researcher education programs.
  • Notable company with rapidly increasing presentations at international conferences.
  • Possesses domestically top-class analysis technology in bioinformatics.
  • Actively supports young researchers in the industry through various grant programs.
  • Early adopter of cloud-based drug discovery platforms.
  • Highly evaluated for growth strategy outlining path to specialized pharmaceutical development.
  • Founder is a young executive born in the 1960s, a topic of discussion.
  • Emphasizes follow-up support after market launch, not just R&D.
  • Maintains competitive edge through advanced IP strategy.

Hidden Connections

  • Has multiple undisclosed joint research contracts with several major domestic pharmaceutical companies, deepening technology exchange.
  • Provides technology to startup support programs in Asian countries to strengthen regional collaboration.
  • Special collaboration with university labs, publishing many joint papers in gene medicine field.
  • Expanding share in domestic biotech market through online drug discovery platform provision.
  • Has multiple advisory contracts with renowned RNA researchers guiding research direction.
  • Conducted fundraising from domestic and international funds immediately after TSE Growth listing to accelerate business.
  • Introduced AI technology undisclosed into new drug development projects of multiple domestic pharmaceutical companies.
  • Number of presentations at international bio conferences is more than twice the industry average.

Future Outlook

Growth Drivers

  • Growing demand for novel therapeutics targeting messenger RNA
  • Improved drug discovery speed through AI-biotech fusion
  • Expansion of joint development with pharmaceutical companies and stabilized fundraising
  • Improved R&D environment through domestic and international regulatory easing
  • Global growth of biopharmaceutical market
  • Market share expansion of diverse drug discovery support services
  • Social demand for sustainable pharmaceutical development
  • Maintenance and strengthening of competitiveness through new technology adoption
  • Aggressive entry into overseas markets
  • Enhanced talent acquisition and development systems
  • Strengthened protection through strategic IP management
  • R&D cost efficiency improvements

Strategic Goals

  • Domestic leadership as messenger RNA specialized pharmaceutical manufacturer
  • Achieve 100 billion yen in global market sales
  • Establish innovative drug discovery platform fusing AI and biotech
  • Build sustainable R&D structure and reduce environmental impact
  • Strengthen partnerships with domestic and international pharmaceutical companies
  • Maximize diverse product lineup and customer satisfaction
  • Top domestic brand for drug discovery education and training programs
  • Establish advanced IP protection system for research outcomes
  • Strengthen community collaborations and expand medical support
  • Promote employee diversity and realize comfortable work environment

Business Segments

Drug Discovery Support Services

Overview
Provides diverse services to accelerate drug discovery development and support improved research efficiency for customers.
Competitiveness
Drug discovery efficiency via RNA target technology and AI utilization
Customers
  • Pharmaceutical companies
  • Biotech ventures
  • University research institutions
  • Public research institutions
  • Chemotherapy research facilities
  • New drug development teams
Products
  • RNA target compound library
  • Drug discovery target analysis service
  • Bioinformatics analysis
  • Drug maturation support tools
  • AI drug discovery platform

Research Reagent Supply

Overview
Stably supplies high-quality research chemicals and reagents to support research activities.
Competitiveness
Thorough quality control and customization capabilities
Customers
  • University labs
  • Corporate R&D departments
  • Medical institution research divisions
  • Clinical trial institutions
Products
  • High-purity RNA extraction reagents
  • Gene cloning reagents
  • Drug efficacy verification assay kits
  • Cell culture kits

Pharmaceutical Joint Development

Overview
Conducts new drug joint development through partnerships with pharmaceutical companies to promote commercialization of research outcomes.
Competitiveness
Proprietary RNA target platform and partnership track record
Customers
  • Major pharmaceutical companies
  • Domestic and international biotech firms
  • Therapeutic development teams
Products
  • Novel messenger RNA target pharmaceuticals
  • Joint research proposals
  • Clinical trial support

Data Analysis Services

Overview
Realizes efficiency and accuracy improvements in drug discovery research through advanced analysis technologies.
Competitiveness
Strength in AI analysis technology and bio-data integration
Customers
  • Drug discovery research institutions
  • Pharmaceutical company development divisions
  • Bioinformatics companies
Products
  • Gene expression analysis
  • AI-powered drug discovery target discovery
  • Clinical data integration analysis

Drug Discovery Platform Provision

Overview
Provides efficient R&D environments tailored for drug discovery ventures.
Competitiveness
Cloud-based integrated drug discovery environment
Customers
  • Biotech startups
  • Mid-sized pharmaceutical companies
  • University ventures
Products
  • Messenger RNA target drug discovery library
  • AI drug discovery tools
  • Online drug discovery platform

Technology Consulting

Overview
Provides support for technology strategies and IP in drug discovery development.
Competitiveness
Integration of drug discovery expertise and patent strategy
Customers
  • Pharmaceutical company labs
  • Bio-related companies
  • University researchers
Products
  • RNA technology adoption support
  • R&D strategy planning
  • Patent acquisition support

Academic Collaboration Programs

Overview
Collaborates with academic institutions to support cutting-edge drug discovery research.
Competitiveness
Broad research network and promotion of exchanges
Customers
  • Universities
  • Public research institutes
  • International joint research institutions
Products
  • Joint research projects
  • Sharing of research materials
  • Educational seminars

Clinical Trial Support Services

Overview
Provides specialized services to streamline clinical trial processes.
Competitiveness
Quality management capabilities specialized in pharmaceutical development
Customers
  • Pharmaceutical company clinical trial divisions
  • Medical institution clinical trial centers
Products
  • Clinical trial data management
  • Case report form creation support
  • Regulatory compliance support

IP Management

Overview
Supports management and utilization of intellectual property rights related to drug discovery.
Competitiveness
Specialized response understanding drug discovery technology
Customers
  • Biotech companies
  • Research institutions
  • Drug discovery ventures
Products
  • Patent filing agency
  • IP strategy development
  • Technology evaluation

Technology Licensing

Overview
Supports business expansion through technology licensing agreements.
Competitiveness
Provision of advanced RNA drug discovery technology
Customers
  • Pharmaceutical companies
  • Medical device manufacturers
Products
  • RNA target technology license
  • Drug discovery platform technology
  • Data analysis algorithms

Contract Manufacturing Services

Overview
Provides contract manufacturing and quality control for drug candidate substances.
Competitiveness
Advanced manufacturing technology and safety management
Customers
  • Biopharmaceutical companies
  • R&D institutions
Products
  • Drug candidate compound manufacturing
  • Trial-use bio-material provision

Clinical Analysis Support

Overview
Supports clinical trial data analysis and safety evaluation.
Competitiveness
Specialized statistical analysis and report creation capabilities
Customers
  • Clinical trial conducting companies
  • Pharmaceutical research divisions
Products
  • Clinical data statistical analysis
  • Safety evaluation report creation

Competitive Advantage

Strengths

  • Uniqueness of messenger RNA target technology
  • Strong partnership relationships with pharmaceutical companies
  • Advanced bioinformatics technology
  • Drug discovery efficiency via AI utilization
  • Lean, elite R&D structure
  • Strategy to transform into specialized pharmaceutical manufacturer
  • Strengthened fundraising base through listing
  • High expertise in biotech drug discovery
  • Broad provision of drug discovery support services
  • Collaboration network with research institutions
  • Deployment of cutting-edge drug maturation support tools
  • Product customization to customer needs
  • Strength in cell culture and drug efficacy evaluation technology
  • Flexible technology consulting structure
  • Stable research reagent supply

Competitive Advantages

  • Differentiation through proprietary drug discovery platform targeting messenger RNA
  • Strength in drug discovery efficiency combining AI and biotech
  • Trust built through joint development experience with pharmaceutical companies
  • Comprehensive capability to provide wide-ranging drug discovery support services
  • Establishment of competitive superiority accompanying transformation to specialized pharmaceutical manufacturer
  • High customer satisfaction through flexible customization
  • Technology evolution leveraging academic collaborations with universities and public institutions
  • Broad phase coverage possible up to clinical trial support
  • Improved fundraising and social credibility through listing
  • Stable supply system for high-quality research reagents
  • Acceleration of R&D outcomes through technology consulting
  • Contribution to development risk reduction via clinical trial support services
  • Enhanced market access utilizing diverse sales channels
  • Rapid implementation and application capabilities for latest technologies
  • Strong network formation with domestic and international biotech ventures

Threats

  • Rapid catch-up by competitors in AI drug discovery technology
  • Increased development costs and timelines due to regulatory strengthening
  • Impact of management changes in partner pharmaceutical companies
  • Risks of delays or disputes in technology patent rights
  • Development stagnation due to difficulties in novel drug discovery target exploration
  • Instabilization of research funding accompanying market environment changes
  • Intensified competition from emerging overseas biotech ventures
  • Growth slowdown due to size limitations of specialized pharmaceutical market
  • Vulnerability of highly externally dependent R&D structure
  • Increased labor costs from intensified talent acquisition competition
  • Risk of inability to keep pace with accelerating technological innovation
  • Impacts from domestic and international political and economic fluctuations

Innovations

2023: Messenger RNA Target Drug Discovery Platform Renewal

Overview
Integrated AI technology to significantly improve speed of drug candidate discovery.
Impact
Shortened drug discovery lead time by 30%

2024: Drug Candidate Compound Library Expansion

Overview
Developed novel RNA modulators and doubled the number of compounds.
Impact
Enabled application to diverse disease areas

2022: AI Drug Discovery Analysis Service Launch

Overview
Commercialized AI-based drug discovery target prediction service.
Impact
Significantly improved customer research efficiency

2023: Drug Maturation Support Tool Enhancement

Overview
Added high-sensitivity evaluation functions to target cell culture kits.
Impact
Improved drug efficacy evaluation accuracy

2021: Bioinformatics Advancement

Overview
Proprietarily developed gene expression analysis algorithms for improved accuracy.
Impact
Contributed to improved drug discovery success rate

2020: New Joint Development Agreement with Pharmaceutical Company

Overview
Collaborated toward clinical trials for messenger RNA target therapeutics.
Impact
Successfully expanded development pipeline

2023: Cloud-Based Drug Discovery Platform Introduction

Overview
Launched online-accessible drug discovery support tools.
Impact
Improved research speed and collaboration efficiency

2024: Patent Acquisition for Novel RNA Target Drug Candidates

Overview
Successfully protected IP for proprietary compound group.
Impact
Leads to strengthened competitive superiority

2022: Clinical Trial Support Service Launch

Overview
Established clinical trial data management and analysis support system.
Impact
Contributed to risk reduction in drug discovery development

2021: Corporate Expansion of Education Programs

Overview
Expanded scale of drug discovery training for companies and universities.
Impact
Contributed to strengthened industry-academia collaboration

Sustainability

  • Introduction of low-environmental-impact technologies in R&D
  • Facility improvements for expanded renewable energy use
  • Active adoption of green chemistry reagents
  • Diverse talent recruitment and diversity promotion
  • Community collaboration for medical contribution activities
  • Promotion of resource-recycling business operations
  • Strengthened ethical business management in pharmaceutical industry
  • Implementation of circular office operations
  • Introduction of energy-efficient research equipment
  • Sustainability awareness enhancement through employee education
  • Technology development support for improved medical access
  • Continuous improvement system via environmental impact assessment